Ecstasy-class analogs and use of same in detection of...

Chemistry: natural resins or derivatives; peptides or proteins; – Proteins – i.e. – more than 100 amino acid residues – Blood proteins or globulins – e.g. – proteoglycans – platelet...

Reexamination Certificate

Rate now

  [ 0.00 ] – not rated yet Voters 0   Comments 0

Details

C435S006120, C435S007710, C435S007930, C435S007940, C435S007700, C435S007720, C436S545000, C436S546000, C436S525000, C436S534000, C530S389800

Reexamination Certificate

active

06946547

ABSTRACT:
The present invention provides a system for the improved detection of ecstasy-class compounds in biological samples. New ecstasy-class analogs are provided for detection of such ecstasy-class drugs. These analogs are compounds, or salts thereof, of a 2-amino-methylenedioxyphenyl (MDP) derivative attached to Z, where Z is a moiety capable of bonding, either directly or indirectly, with an immunogenic carrier, a detectable label, or a solid capture vehicle. Such analogs may be used to construct immunogens, enzyme or enzyme-donor conjugates, and other conjugates. The immunogens reproducibly generate antibodies with an exquisite ability to distinguish various ecstasy-class drugs in biological samples from potentially interfering substances. The specific antibodies and the conjugates may be used to distinguish and measure various ecstasy-class compounds in biological samples, such as those obtained from an individual suspected of substance abuse. In another aspect, the invention includes certain reagents, reagent combinations, and kits for performing assay methods for ecstasy-class compounds in a biological sample.

REFERENCES:
patent: 4708929 (1987-11-01), Henderson
patent: 5248791 (1993-09-01), Brynes et al.
patent: 5470997 (1995-11-01), Buechler et al.
patent: 5488114 (1996-01-01), Shigetoh et al.
patent: 5501987 (1996-03-01), Ordonez
patent: 5618926 (1997-04-01), Salamone et al.
patent: 5760184 (1998-06-01), Swain et al.
patent: 5876727 (1999-03-01), Swain et al.
patent: 5976812 (1999-11-01), Huber et al.
patent: 6306616 (2001-10-01), Shindelman
patent: 0363041 (1990-04-01), None
patent: 0371253 (1990-06-01), None
patent: 0574782 (1993-12-01), None
patent: 9610179 (1996-04-01), None
patent: 0114371 (2001-03-01), None
Amaiz et al,Preparation of N-heterocyclic derivatives as NOS Inhibitors, Chemical Abstract No 129:231019 & WO 98/37079A1 (See compound with Reg. No. 212635-56-8).
Belke, J. et al.,Immunoaffinity extraction of morphine, morphine-3-glucuronide and morphine-6-glucuronide from blood of heroin victims for simultaneous high-performance liquid chromatographic determination, Journal of Chromatography B, 726 (1999), pp. 111-119.
Bellet, Neal,Enhanced Detection of Benzodiazepines by Immunoassay, Journal of Analytical Toxicology, vol. 21, Jan./Feb. 1997, p. 76.
Boehringer Mannheim,Cedia Dau Opiate,Boehringer Mannheim, Catalog Nos. 1557386, 1661175, 1661248, May 1996, 98-695-1.
Boehringer Mannheim,Oplate-Qualitative,Boehringer Mannheim, Kit Catalog Nos. 1557386, 1661175, 1661248, pp. 1-15.
Chandrakumar, Nizal S. et al.,Phenylphosphonate Monoester Analogs of Cocaine, Potential Haptens for the Generation of Catalytic Antibodies,Bioorganic & Medicinal Chemistry Letters, vol. 3, No. 2, 1993, pp. 309-312.
Charbonnier, Jean-Baptiste et al.,Crystal structure of the complex of a catalytic antibody Fab fragment with a transition state analog: Structural similarities in esterase-like catalytic antibodies,Biochemistry, Proc. Natl. Acad. Sci. USA, vol. 92, Dec. 1995, pp. 11721-11725.
Clifton, ftp://hyperreal.com/drugs/misc/shulgin.visit, Nov. 11, 1996, pp. 1-5.
Cody, John T. et al.,Fluorescence Polarization Immunoassay Detection of Amphetamine, Methamphetamine, and Illicit Amphetamine Analogues,Journal of Analytical Toxicology, vol. 17, Jan./Feb. 1993, pp. 26-30.
Cone, Edward J. et al.,Forensic Drug Testing for Opiates. V. Urine Testing for Heroin, Morphine, and Codeine With ommerical Opiate Immunoassays,Journal of Analytical Toxicology, vol. 17, May/Jun. 1993, pp. 156-164.
Cone, Edward J. et al.,Forensic Drug Testing For Opiates. IV. Analytical Sensitivity, Specificity, and Accuracy of Commercial Urine Opiate Immunoassays,Journal of Analytical Toxicology, vol. 16, Mar./Apr. 1992, pp. 72-78.
Cone, Edward J. et al.,Forensic Drug Testing for Opiates: I. Detection of 6-Acetylmorphine in Urine as an Indicator of Recent Heroin Exposure: Drug and Assay Considerations and Detection Times,Journal of Analytical Toxicology, vol. 15, Jan./Feb. 1991, pp. 1-7.
Coty, William A. et al.,CEDIA R Homogeneous Immunoassays: Current Status and Future Prospects,Journal of Clinical Immunoassay, Ffall 1994, vol. 17, No. 3, pp. 144-150.
Derks, H.J.G.M. et al.,Determination of the Heroin Metabolite 6-Acetylmorphine by High-Performance Liquid Chromatography Using Automated Pre-Column Derivatization and Fluorescence Detection,Journal of Chromatography, 370, 1986, pp. 173-178.
Diagnostics Reagents, Inc.,Opiate Enzyme Immunoassay,Diagnostics Reagents, Inc., Oct. 1998, pp. 1-2.
Elliott, H.W. et al.,Actions and metabolism of heroin administered by continuous intravenous infusion to man,Clinical Pharmacology and Therapeutics, vol. 12, No. 5, pp. 806-814.
ElSohly, Mahmoud A.,Drug Testing in the Workplace: Could a Postive Test for One of the Mandated Drugs Be for Reasons Other Than Illicit Use of the Drug?,Journal of Analytical Toxicology, vol. 19, Oct. 1995, pp. 450-458.
Fay, John et al.,Detection of Methamphetamine in Sweat by EIA and GC-MS,Journal of Analytical Toxicology, vol. 20, Oct. 1996, pp. 398-403.
Fehn, Josef et al.,Detection of O6-Monoacetylmorphine in Urine Samples by GC/MS as Evidence for Heroin Use,Journal of Analytical Toxicology, vol. 9, May/Jun. 1985, pp. 134-138.
Fu et al.,Synthesis and vasodilating activity of benzamide and cinnamide derivatives,Chemical Abstract No. 131:111148, (1999), 34(2), 109-113.
Galloway, F. Roark et al.,Methadone Conversion to EDDP during GC-MS Analysis of Urine Samples,Journal of Analytical Toxicology, vol. 23, Nov./Dec. 1999, pp. 615-619.
George, S. et al.,A Pilot Study to Determine the Usefulness of the Urinary Excretion of Methadone and its Primary Metabolite(EDDP)as Potential Markers of Compliance in Methadone Detoxification Programs,Journal of Analytical Toxicology, vol. 33, Mar./Apr. 1999, pp. 81-85.
Gerhards, Petra et al.,Determination of Designer Drugs and Ecstasy,Git LaborMedizin, May 1996, pp. 212-216.
Giroud, C. et al.,2C-B: A New Psychoactive Phenylethylamine Recently Discovered in Ecstasy Tablets Sold on the Swiss Black Market,Journal of Analytical Toxicology, vol. 22, Sep. 1998, pp. 345-354.
Glare, P.A. et al.,Clinical Pharmacokinetics of Morphine,Therapeutic Drug Monitoring, 13, (1991), pp. 1-23.
Granquist, Lamont,#156 TM; 4-TM; 4-Thiomescaline,Phenethylamines I Have Known and Loved, Nov. 21, 1996, pp. 1-5.
Granquist, Lamont#8 Arladne: 4C-DOM; BL-3912: Dimoxamine,Phenethylamines I Have Known and Loved, Nov. 21, 1996, pp. 1-5.
Granquist, Lamont,#157 TMA; 3,4,5-Trimethoxyamphetamine,Phenethylamines I Have Known and Loved, Nov. 21, 1996, pp. 1-7.
Granquist, Lamont,Quick Index to PiHKAL,lamont@hyperreal.com, Oct. 31, 1994, pp. 1-3.
Granquist, Lamont,#142 PEA; Phenethylamine,Phenethylamines I Have Known and Loved, Nov. 21, 1996, pp. 1-4.
Hanisch, W. et al.,Determination of the Heroin Metabolite 6-Monoacetylmorphine in Urine by High-Performance Liquid Chromatography with Electrochemical Detection,Journal of Analytical Toxicology, vol. 17, Jan./Feb. 1993, pp. 48-50.
Henderson, Daniel R. et al.,CEDIA, a New Homogeneous Immunoassay System,Clinical Chemistry, vol. 32, No. 9, 1986, pp. 1637-1641.
Huestis, Marilyn A. et al.,Detection Times of Marijuana Metabolites in Urine by Immunoassay and GC-MS,Journal of Analytical Toxicology, vol. 19, Oct. 1995, pp. 443-449.
Jenkins, Amanda J. et al.,6-Acetylmorphine Detection in Postmortem Cerebrospinal Fluid,Journal of Analytical Toxicology, vol. 22, Mar./Apr. 1998, pp. 173-175.
Khanna, P.L. et al.,A recombinant protein-based homogeneous immunoassay,Americal Clinical Laboratory, Oct. 1989, pp. 1-5.
Khanna, Pyare L. et al.,A new homogenous enzyme immunoassay using recombinant enzyme fragments,Clinica Chimica Acta, 185 (1989), pp. 231-240.
Kintz, Pascal et al.,Immunassay Responses of MBDB,Journal of Analytical Toxicology, vol. 21, Nov./Dec. 1997, pp. 589-590.
Lin, Dong-Liang et al.,Determination of Codeine, Morphine and 6-Acetylmorphine in Urine,Journal of Food and Drug Analysis, 1996. 4(1): 25-34.
Lingenfelter, C. et al.,CEDIA EDDP(Methadone Metabolite)Assay for Urine Drug Testing,Roche Diagnostics, Boehringer Mannheim Corpor

LandOfFree

Say what you really think

Search LandOfFree.com for the USA inventors and patents. Rate them and share your experience with other people.

Rating

Ecstasy-class analogs and use of same in detection of... does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Ecstasy-class analogs and use of same in detection of..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Ecstasy-class analogs and use of same in detection of... will most certainly appreciate the feedback.

Rate now

     

Profile ID: LFUS-PAI-O-3401597

  Search
All data on this website is collected from public sources. Our data reflects the most accurate information available at the time of publication.